Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

  • 📰 AP
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 51%

France Nouvelles Nouvelles

France Dernières Nouvelles,France Actualités

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions reach the U.S. market in July.

HELENA, Mont. — Montana’s Republican governor indicated Monday he would sign a bill to ban gender-affirming medical care for transgender minors, but he suggested changes to make it clear that public funds could not be used to pay for surgery or hormone treatments for youth diagnosed with gender

A biosimilar is a lower-cost version of a biologic that is approved by the Food and Drug Administration after regulators determine that it is highly similar to the original product. It’s not the same as a generic drug, which is a copy of a chemical-based medicine that is easier — and cheaper — to make.

Pharmacy benefits managers, or PBMs, manage prescription drug coverage for insurers, employees and other big clients.Generally, yes, but how that affects a patient will depend on the drug and the coverage. Amgen said in January that it will offer its biosimilar, Amjevita, at prices 5% and 55% below Humira’s list price.This will vary, depending on the PBM and the employer or insurer that designs the coverage.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 728. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités